SEC Tracker
Get the app

Trevi Therapeutics TRVI

Trevi Therapeutics reported a net loss of $21.45 million for the three months ended Sep 30, 2026.

Trevi Therapeutics (TRVI) filed a 10-Q with the SEC on Nov 9, 2026, 4:28 pm ET. Source: the filing on SEC EDGAR.

Form
10-Q
Filed
Importance
Notable
  1. Net loss: $21.45 million for the three months ended Sep 30, 2026
  2. Diluted EPS: -$0.13 for the three months ended Sep 30, 2026
  3. Cash and equivalents: $27.85 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Trevi Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What changed since last quarter

No new risk factors or legal mentions.

Compared with the 10-Q for the period ended Jun 30, 2026.

Key numbers from the XBRL in this filing and the previous one.
This filingPreviousChange vs prior 10-Q
Operating income and margin−$24.49M−$20.51M−19%
Net income−$21.45M−$17.8M−21%
Operating cash flow−$19.69M−$17.43M−13%
Cash$27.85M$54.3M−49%

Data on this page was fetched . The filing on SEC.gov is the record.